From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
Benufutamab (GEN1029) is a death receptor 5(DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5(DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Quercetin 3,4′-dimethyl ether (3,4′-Dimethylquercetin) is a dimethoxyflavone can be isolated from Combretum quadrangulare. Quercetin 3,4′-dimethyl ether overcomes TRAIL resistance by enhancing DR5 expression and has anti-tumor activity .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis [5].
P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 R175H, p53 R248W and p53 R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5(DR5). P53R3 is used for cancer research .
Cyproterone acetate is an anti-androgen (IC50=7.1 nM) and progestogen synthetic steroid. Cyproterone acetate has affinity with progesteron and with glucocorticoidal receptors .
Benufutamab (GEN1029) is a death receptor 5(DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5(DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM) .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5(DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis [5].
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (127a.a, HEK293, His) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (127a.a, HEK293, His) is 127 a.a., with molecular weight of ~18.0 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His-Avi) is 127 a.a., with molecular weight of 20-25 kDa.
TRAIL R2/TNFRSF10B Protein, a receptor for TNFSF10/TRAIL, activates apoptosis through FADD-mediated recruitment of caspase-8, forming the death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, crucial for ER stress-induced apoptosis. In its monomeric form, it interacts with TRADD and RIPK1. Upon stimulation, enhanced interactions occur with BIRC2, DDX3X, and GSK3B, leading to DDX3X and BIRC2 cleavage. TRAIL R2/TNFRSF10B Protein, Mouse (128a.a, HEK293, His) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293, with C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (128a.a, HEK293, His) is 128 a.a., with molecular weight of 30-40 kDa.
TRAIL R2/TNFRSF10B Protein, a receptor for TNFSF10/TRAIL, initiates apoptosis by recruiting caspase-8 via FADD. It forms the death-inducing signaling complex (DISC), activating caspases and mediating apoptosis. TRAIL R2/TNFRSF10B also activates NF-kappa-B and plays a crucial role in endoplasmic reticulum stress-induced apoptosis. In its monomeric state, it interacts with TRADD and RIPK1, and stimulation enhances interactions with BIRC2 and DDX3X. Notably, it interacts with HCMV protein UL141, highlighting its multifaceted role in apoptotic and signaling pathways. TRAIL R2/TNFRSF10B Protein, Human (HEK293, His-Avi) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (HEK293, His-Avi) is 127 a.a., with molecular weight of 20-25 kDa.
TRAIL R2/TNFRSF10B Protein serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. Upon ligand binding, the adapter molecule FADD recruits caspase-8 to the activated receptor, forming the death-inducing signaling complex (DISC). This activation leads to a cascade of caspases, mediating apoptosis. TRAIL R2/TNFRSF10B lacks conserved residue(s) crucial for feature annotation propagation. TRAIL R2/TNFRSF10B Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293, with C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Cynomolgus (HEK293, His) is 155 a.a., with molecular weight of 25-35 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by E. coli , with tag free. The total length of TRAIL R2/TNFRSF10B Protein, Human is 132 a.a., with molecular weight of ~14.8 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His-Fc) is 125 a.a., with molecular weight of 50-55 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His) is 127 a.a., with molecular weight of ~15.8 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK 293, hFc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK 293, hFc) is 125 a.a., with molecular weight of ~50 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (HEK293, hFc) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (HEK293, hFc) is 127 a.a., with molecular weight of ~41 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, Avi-His) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, Avi-His) is 125 a.a., with molecular weight of 20-40 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, hFc) is 125 a.a., with molecular weight of 50-75 kDa.
DR5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to DR5. It can be used for WB,IP,IHC-P,FC assays with tag free, in the background of Human.
Inquiry Online
Your information is safe with us. * Required Fields.
